Valeant Pharmaceuticals International Inc. said it expects a profit of 44 cents to 48 cents per share in the fourth quarter, and it now expects to report $510 million to $520 million in revenue, up from a prior estimate of $500 million.
Johnson & Johnson said that it requested approval to sell its blood thinner rivaroxaban for the prevention of stroke and embolism in patients with atrial fibrillation.
Merck & Co. said U.S. and European regulators accepted its potential hepatitis C treatment boceprevir for expedited review. The U.S. Food and Drug Administration gave the drug application priority review status and will aim to complete its review in six months.
Ligand Pharmaceuticals Inc. said it licensed two liver disease drugs to drugmaker Chiva Pharmaceuticals Inc. as part of a deal that could be worth more than $100 million.
Immutep S.A. announced the execution of a licence agreement granting GSK exclusive worldwide rights to ImmuTune IMP731 and any other antibodies that deplete LAG-3 positive cells.
Tharo Systems, Inc. has introduced its UHF Generation 2 RFID reader for under $1,000. The PR100 features an LCD display, long battery life, and is capable of saving up to 4,000 RFID scans in its internal memory.
GelJacket from Caron Products is an active gel insulation technology. It is incorporated inside every wall of the incubator chamber, resulting in a product with thermal advantages that far surpass any CO2 incubator on the market.
Hepregen Corporation, a provider of bioengineered solutions to improve patient outcomes, has extended and expanded its agreement with Boehringer Ingelheim Pharmaceuticals, Inc. for the adoption of its proprietary technology platform, HepatoPac.
A new, simplified method for producing large amounts of viral vector cassettes capable of shuttling genes into host cells will help advance the promising field of gene therapy as applications move into large animal studies and human clinical trials.
When vaccinating children against chicken pox, researchers have found, two doses are better than one. In fact, the odds of developing chicken pox were 95% lower in children who had received two doses of the vaccine compared with those who had received only one dose.
NovaBay Pharmaceuticals announces that in tests conducted at a third-party laboratory, NovaBay's NVC-422 has shown in vitro activity against the "superbug" NDM-1-encoded Klebsiella pneumoniae at a very low concentration of 2 mg/mL.
CeNeRx BioPharma, Inc., reported that it has initiated a Phase 2 trial of its new formulation of TriRima, the company’s novel antidepressant in development as monotherapy for treatment resistant depression.
Hundreds of women in Britain have complained after becoming pregnant despite using a contraceptive implant that is supposed to work for years. But the implant's maker, Merck & Co., says the failure rate isn't exceptional, and that women should continue to use it.
Seattle Genetics Inc. will receive $8 million from Pfizer Inc. for rights to use its cancer-fighting antibody-drug conjugate technology. The company could receive more than $200 million in milestone and royalty payments for any products that stem from the agreement.
Athersys, Inc. announced that it has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem to patients being treated for leukemia or other blood born cancers.